Insypher

InSypher is a biotechnology company spun out from the University of Oxford that specializes in the discovery of cell-permeable cyclic peptide therapeutics. The company utilizes a proprietary "in-cell" screening platform that allows for the direct identification of peptides capable of crossing cell membranes and hitting intracellular targets. This approach addresses a major bottleneck in peptide drug discovery, where many potent binders fail due to poor permeability. InSypher's technology is designed to target "undruggable" intracellular protein-protein interactions, with an initial focus on oncology and epigenetic regulators. By identifying cell-permeable leads directly within the cellular environment, the company aims to accelerate the development of precision medicines for complex diseases. The firm is backed by Oxford Science Enterprises and is built upon the foundational research of Professor Akane Kawamura.